Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 13/20 | 1.00 |
| ▸ | F2 | P00734 | 5/20 | 1.00 |
| ▸ | HGFAC | Q04756 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | PLG | P00747 | 2/20 | 1.00 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | C1R | P00736 | 1/20 | 1.00 |
| ▸ | F10 | P00742 | 1/20 | 1.00 |
| ▸ | F12 | P00748 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 1/20 | 1.00 |
| ▸ | HPN | P05981 | 1/20 | 1.00 |
| ▸ | KLK1 | P06870 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 1/20 | 1.00 |
| ▸ | C1S | P09871 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL29358879 | 1.00 | PRSS1 (1.00) | PRSS1F2HGFACALDH1A1PLG | |
| Nafamostat SCHEMBL29360143 | 1.00 | PRSS1 (1.00) | PRSS1F2HGFACALDH1A1PLG | |
| Nafamostat SCHEMBL25197320 | 0.93 | FTO (1.00) | PRSS1F2HGFACALDH1A1PLG | |
| Nafamostat SCHEMBL1650158 | 0.93 | FTO (1.00) | PRSS1F2HGFACALDH1A1PLG | |
| SCHEMBL31380450 | 0.87 | F12 (0.76) | PRSS1F2HGFACALDH1A1PLG | |
| SCHEMBL23898923 | 0.86 | PRSS1 (0.76) | PRSS1F2HGFACALDH1A1PLG | |
| SCHEMBL25633204 | 0.86 | PRSS1 (0.76) | PRSS1F2HGFACALDH1A1PLG | |
| SCHEMBL7337750 | 0.83 | F12 (0.71) | PRSS1F2HGFACALDH1A1PLG | |
| SCHEMBL7338848 | 0.83 | F12 (0.71) | PRSS1F2HGFACALDH1A1PLG | |
| SCHEMBL7342376 | 0.83 | F12 (0.71) | PRSS1F2HGFACALDH1A1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3828 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636253-B2 | Modified release compositions of nafamostat and methods of using same | Ensysce Biosciences Inc. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260139035-A1 | HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2026-05-21 | — | — | US | claimed |
| EP-3934635-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | ENSYSCE BIOSCIENCES INC (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260130921-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | AcuraStem Incorporated (US) | 2026-05-14 | — | — | US | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12599644-B2 | Treatment of coronavirus infection with Flt3 receptor interacting lectin (FRIL) | ACADEMIA SINICA (TW) | 2026-04-14 | — | — | US | claimed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260007597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2026-01-08 | — | — | US | claimed |
| US-20250361205-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | ENSYSCE BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20030077229-A1 | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs | NOVADEL PHARMA INC. | 2003-04-24 | — | — | US | claimed |
| EP-0801953-B1 | Medical device for the extracorporal blood or plasma treatment and methods for the manufacture of such device | HOSPAL IND (FR) | 2002-07-03 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5709993-A | Process for anticoagulation during extracorporeal blood circulation sequentially using citrate or nafamostat and heparin | BUTUROVIC-PONIKVAR JADRANKA (SI) | 1998-01-20 | — | — | US | claimed |
| EP-0801953-A1 | Medical device for the extracorporal blood or plasma treatment and methods for the manufacture of such device | HOSPAL INDUSTRIE (FR) | 1997-10-22 | — | — | EP | claimed |
| EP-0647398-B1 | ORGAN PRESERVING FLUID | TORII PHARMACEUTICAL CO LTD (JP) | 1997-09-17 | — | — | EP | claimed |
| US-5565317-A | BIOLOGICAL ORGAN PRESERVATIVE; STORAGE STABILITY | TORII PHARMACEUTICAL CO., LTD. (JP) | 1996-10-15 | — | — | US | claimed |
| EP-0647398-A1 | ORGAN PRESERVING FLUID | TORII PHARMACEUTICAL CO., LTD (JP) | 1995-04-12 | — | — | EP | claimed |